Global peptide therapeutics market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing prevalence of chronic diseases such as cancer and metabolic disorders, which are major drivers for the growth of this market. In addition, increasing awareness about peptide therapeutics among physicians and patients is also driving the growth of this market.
The global peptide therapeutics market can be segmented on the basis of type into injection and oral; on the basis of application into cancer, metabolic disorders, central nervous system; and on the basis of region into North America, Latin America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA). The global peptide therapeutics market has been segmented based on type into injection and oral; based on application into cancer, metabolic disorders and central nervous system; based on region into North America (NA), Latin America (LA), Europe (EU), APAC (APAC) and MEA regions.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as diabetes, cancer, cardiovascular disease and obesity are driving the growth of the global peptide therapeutics market due to their high incidence rates globally and their associated high treatment costs which are expected to increase over time with no signs of slowing down in developed countries like US and Europe or developing countries like China or India.
- Rising demand for cost-effective treatments in emerging economies such as China and India is also driving the growth of the global peptide therapeutics market due to their large populations with limited access to healthcare services which has led them towards adopting more affordable treatment options that can be afforded by most people living in these regions including peptides therapies which are relatively cheaper than other conventional drugs used for treating chronic diseases like diabetes or cancer .
Industry Growth Insights published a new data on “Peptide Therapeutics Market”. The research report is titled “Peptide Therapeutics Market research by Types (Injection, Oral, Other), By Applications (Cancer, Metabolic Disorders, Central Nervous System, Other), By Players/Companies Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, Shire, AbbVie, Ipsen, Allergan, Ferring, Merck, The Medicines, Roche, J & J”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Peptide Therapeutics Market Research Report
By Type
Injection, Oral, Other
By Application
Cancer, Metabolic Disorders, Central Nervous System, Other
By Companies
Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, Shire, AbbVie, Ipsen, Allergan, Ferring, Merck, The Medicines, Roche, J & J
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Peptide Therapeutics Market Report Segments:
The global Peptide Therapeutics market is segmented on the basis of:
Types
Injection, Oral, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Metabolic Disorders, Central Nervous System, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Teva
- Novo Nordisk
- Takeda
- Eli Lilly
- AstraZeneca
- Novartis
- Shire
- AbbVie
- Ipsen
- Allergan
- Ferring
- Merck
- The Medicines
- Roche
- J & J
Highlights of The Peptide Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Oral
- Other
- By Application:
- Cancer
- Metabolic Disorders
- Central Nervous System
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Peptide Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Peptide Therapeutics is a biotechnology company that specializes in the development and commercialization of peptide therapeutics. Peptides are short, linear proteins composed of amino acids. They are typically smaller than 20 amino acids long and can interact with specific receptors on cells to exert biological effects. Peptides have been shown to have a variety of therapeutic potential, including for the treatment of cancer, inflammation, and other diseases.
Some of the key players operating in the peptide therapeutics market are Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, Shire, AbbVie, Ipsen, Allergan, Ferring, Merck, The Medicines, Roche, J & J.
The peptide therapeutics market is expected to grow at a compound annual growth rate of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Peptide Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Peptide Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Peptide Therapeutics Market - Supply Chain
4.5. Global Peptide Therapeutics Market Forecast
4.5.1. Peptide Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Peptide Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Peptide Therapeutics Market Absolute $ Opportunity
5. Global Peptide Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Peptide Therapeutics Market Size and Volume Forecast by Type
5.3.1. Injection
5.3.2. Oral
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Peptide Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Peptide Therapeutics Market Size and Volume Forecast by Application
6.3.1. Cancer
6.3.2. Metabolic Disorders
6.3.3. Central Nervous System
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Peptide Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Peptide Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Peptide Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Peptide Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Peptide Therapeutics Demand Share Forecast, 2019-2029
9. North America Peptide Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Peptide Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Peptide Therapeutics Market Size and Volume Forecast by Application
9.4.1. Cancer
9.4.2. Metabolic Disorders
9.4.3. Central Nervous System
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Peptide Therapeutics Market Size and Volume Forecast by Type
9.7.1. Injection
9.7.2. Oral
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Peptide Therapeutics Demand Share Forecast, 2019-2029
10. Latin America Peptide Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Peptide Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Peptide Therapeutics Market Size and Volume Forecast by Application
10.4.1. Cancer
10.4.2. Metabolic Disorders
10.4.3. Central Nervous System
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Peptide Therapeutics Market Size and Volume Forecast by Type
10.7.1. Injection
10.7.2. Oral
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Peptide Therapeutics Demand Share Forecast, 2019-2029
11. Europe Peptide Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Peptide Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Peptide Therapeutics Market Size and Volume Forecast by Application
11.4.1. Cancer
11.4.2. Metabolic Disorders
11.4.3. Central Nervous System
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Peptide Therapeutics Market Size and Volume Forecast by Type
11.7.1. Injection
11.7.2. Oral
11.7.3. Other
11.8. Basis Point Share (BPS) Anlysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Peptide Therapeutics Demand Share, 2019-2029
12. Asia Pacific Peptide Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Peptide Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Peptide Therapeutics Market Size and Volume Forecast by Application
12.4.1. Cancer
12.4.2. Metabolic Disorders
12.4.3. Central Nervous System
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Peptide Therapeutics Market Size and Volume Forecast by Type
12.7.1. Injection
12.7.2. Oral
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Peptide Therapeutics Demand Share, 2019-2029
13. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Peptide Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Peptide Therapeutics Market Size and Volume Forecast by Application
13.4.1. Cancer
13.4.2. Metabolic Disorders
13.4.3. Central Nervous System
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Peptide Therapeutics Market Size and Volume Forecast by Type
13.7.1. Injection
13.7.2. Oral
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Peptide Therapeutics Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Peptide Therapeutics Market: Market Share Analysis
14.2. Peptide Therapeutics Distributors and Customers
14.3. Peptide Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Teva
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novo Nordisk
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Takeda
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lilly
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AstraZeneca
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Shire
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. AbbVie
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Ipsen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Allergan
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Ferring
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Merck
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. The Medicines
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Roche
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. J & J
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
